Preclinical studies of MLL-rearranged leukemias have demonstrated a critical role of this enzyme for leukemogenesis, as well as preferential leukemia cytotoxicity with DOT1L inhibition (e.g., EPZ004777) (113–115). The gene discussed is KMT2A; the disease is leukemia.